ALAlphabet Inc.

Institutional investor · Portfolio as of Q2 2024

Top Holdings42 positions

Checking export access…
Activity:

GITLAB INCCL A

9.8M$485.2M24.6%$54.98-9.56%
9 qtrssince 2022-Q2
Unchanged
0
ARMARM
ADR

ARM HOLDINGS PLC

2M$320.8M16.3%$53.52+205.72%
4 qtrssince 2023-Q3
Unchanged
0

REVOLUTION MEDICINES INC

5.3M$206M10.4%$28.69+35.27%
3 qtrssince 2023-Q4
Increased
60

CROWDSTRIKE HLDGS INC

427,895$164M8.3%$30.67+212.38%
7 qtrssince 2022-Q4
Decreased
0

FRESHWORKS INCCL A

12.3M$156.6M7.9%$20.84-39.12%
11 qtrssince 2021-Q4
Unchanged
0

DEXCOM INC

1M$117.6M6.0%$115.76-2.05%
20 qtrssince 2019-Q3
Decreased
0

UIPATH INC CLASS A

7M$89.2M4.5%$67.93-81.33%
13 qtrssince 2021-Q2
Unchanged
0

PRIME MEDICINE INC

15.1M$77.4M3.9%$16.12-68.11%
7 qtrssince 2022-Q4
Unchanged
0

SNOWFLAKE INC

535,604$72.4M3.7%$229.13-41.04%
10 qtrssince 2022-Q1
Unchanged
0
VERVVERVDelisted

VERVE THERAPEUTICS INC

12.3M$60.3M3.1%——
13 qtrssince 2021-Q2
Unchanged
0

PLANET LABS PBC

31.9M$59.4M3.0%$6.15-69.76%
11 qtrssince 2021-Q4
Unchanged
0

TEMPUS AI INCCL A

1.6M$54.3M2.7%$35.000.00%
1 qtr
New
77

SANA BIOTECHNOLOGY INC

2.8M$15.4M0.8%$33.47-83.69%
14 qtrssince 2021-Q1
Unchanged
0

RELAY THERAPEUTICS INC

1.6M$10.2M0.5%$41.71-84.37%
16 qtrssince 2020-Q3
Unchanged
0

VERA THERAPEUTICS INC

241,264$8.7M0.4%——
13 qtrssince 2021-Q2
Unchanged
0

LYELL IMMUNOPHARMA INC

5.9M$8.5M0.4%$324.80-91.07%
13 qtrssince 2021-Q2
Unchanged
0

OSCAR HEALTH INC CLASS A

481,988$7.6M0.4%$26.88-41.15%
14 qtrssince 2021-Q1
Unchanged
0

BEAM THERAPEUTICS INC

321,604$7.5M0.4%$18.00+30.17%
18 qtrssince 2020-Q1
Unchanged
0

TSCAN THERAPEUTICS INC

1.1M$6.3M0.3%$8.34-29.86%
12 qtrssince 2021-Q3
Unchanged
0

ILLUMINA INC

53,470$5.6M0.3%$394.56-66.95%
12 qtrssince 2021-Q3
Unchanged
0
$2B
AUM
42
Positions
Q2 2024
Filing
HI score · 2.5/5
Quarterly 13F Value Change
+5%Q1'23$1.8B+3%Q2'23$1.9B-16%Q3'23$1.6B+39%Q4'23$2.2B+17%Q1'24$2.5B-21%Q2'24$2B
Activity profile
$ moved · Q2'24
New16%Increased10%Decreased66%Exited8%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.3 years
<1Q5%1-4Q10%1-2Y86%2Y+0%

Alphabet Inc. manages $2B across 42 positions as of Q2 2024. Top holdings: GTLB (24.6%), ARM (16.3%), RVMD (10.4%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q2 2024 Summary

Added 2 new positions, exited 3, increased 1, trimmed 2. Top move: TEM (NEW, conviction 77). Portfolio: $2.0B across 42 positions.

Top holdings by portfolio weight

Total AUM$2B
GTLB24.58%
ARM16.25%
RVMD10.43%
CRWD8.31%
FRSH7.93%
DXCM5.96%
PATH4.52%
PRME3.92%
SNOW3.66%
VERV3.05%
Other3.01%

Portfolio allocation by GICS sector

Sectors4
Technology65.24%
Healthcare28.26%
Unknown3.49%
Industrials3.01%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Technology, Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L48
Conviction36
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used